Voluntary nationwide recall: Clonazepam (Endo – July)
Sep. 2024Pharmacy Updates
Endo USA Inc. has recalled one lot of Clonazepam Orally Disintegrating Tablets, USP (C-IV) 0.25 mg. Clonazepam is used to treat panic disorder and certain seizures.
This product is being recalled because the cartons of some packs show the product strength as 0.125 mg, not 0.25 mg, due to an error at a third-party packager. The blister strips inside the product pack reflect the correct strength of 0.25 mg.
Using this drug at a higher dose than prescribed may cause sleepiness, dizziness, loss of muscle control, and confusion.
As of July 16, there had been no reports of adverse events related to this recall.
To learn more about this recall:
- Call Inmar Inc. at 1-877-890-0765. Help is available Monday through Friday from 9 a.m. to 5 p.m. ET.
- Visit the FDA website.
Recent Announcements
CME Webinar: American Foundation for Suicide Prevention’s ‘Talk Saves Lives’ Program
Please join us on Tuesday, April 28, from noon to 1 p.m. for “Talk Saves Lives: An Introduction to Suicide Prevention.” This live, CME-accredited webinar is the American Foundation for Suicide Prevention’s flagship suicide prevention education program. It covers the scope of this leading cause of death, warning signs and risk factors for suicide, and strategies to prevent it.Feb. 2026Education/Webinars
Training Webinar: Conversio Health COPD Management Program
Please join us for a live training webinar by UPMC Health Plan that will provide an overview of a comprehensive COPD management program from Conversio Health.Jan. 2026Education/Webinars
Provider Directory Updates and Required Attestation
As you know, UPMC Health Plan requires all providers to verify their provider directory information at least every 90 days (quarterly).Jan. 2026Important Notices